posted
I do believe they are poised to be a player in this bird flu mania. Even though the P.R. wasnt all that great, look at STTK and there bird flu CONNECTION ----HHMMM make a referance to bird flu and our RFID poultry monitoring and containment system,,,,,,,YES THATS IT AND WHAM the stock goes up 800%%%. THE LIST GOES ON AND ON for the Bird flu Stocks and there big gains. Im in Gtha and will buy more while the price is still low!!!! there should be another P.R. SOON ABOUT THIS AND WHEN IT COMES OUT WHO KNOW WHERE THE TOP WILL BE. HOPEFULLY 1.80 LIKE STTK....... GOOD LUCK TO ALL
Posts: 238 | From: Us | Registered: Aug 2005
| IP: Logged |
posted
In case someone didnt see the P.R. yesterday that made GTHA GO UP 120% HERE IT IS,
PURIVAX (TM) Technology from GeneThera Can Facilitate Faster Development of Avian Flu Vaccine THURSDAY, APRIL 06, 2006 10:00 AM - BusinessWire
WHEAT RIDGE, Colo., Apr 06, 2006 (BUSINESS WIRE) -- GeneThera (GTHA) announces that its Purivax(TM) technology -- a large-scale process for highly purified and high viral titer Adenovirus and AAV recombinant vectors, would enable fast track development of Adenovirus and AAV-based recombinant DNA vaccines for diseases such as the Avian Flu (commonly called Bird Flu).
GeneThera's PURIVAX(TM), is a multi-resin anion exchange chromatography system that dramatically improves biological purity and viral titer of recombinant Adenovirus and AAV vectors. PURIVAX(TM), completely eliminates toxic side effects associated with adenoviruses and AAV vectors thereby making it possible to quickly develop highly immunogenic and safe recombinant DNA vaccines, which are significantly more efficacious in fighting today's bacterial and viral diseases like Bird Flu, as well as food pathogen applications.
Importantly, recombinant DNA (rDNA) vaccine technology represents a powerful tool for an innovative vaccine design process known as "genetic immunization."
Dr. Tony Milici, CEO of GeneThera remarked, "GeneThera's PURIVAX(TM) is able to achieve both high purity and high viral titer (up to 10e16 viral particles/eulate) based on its proprietary multi-resin anion exchange chromatography system, unlike traditional technologies and first generation chromatography processes that are inadequate, both in terms of purity and yield. The important significance to mankind is that our PURIVAX(TM) technology can help achieve accelerated development of an rDNA vaccine for veterinary diseases, such as the Bird Flu."
ABOUT GENETHERA, INC.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide.
Posts: 238 | From: Us | Registered: Aug 2005
| IP: Logged |
posted
GTHA took a hit friday on unverified rumors denied by management that there was a take over and bk in progress. The emphatic denial of the UK rumor and the potential of GTHA avian flu treatment should make for some interesting developments here.
Posts: 660 | From: california | Registered: Nov 2005
| IP: Logged |
posted
Should be interesting today coming off some correction from the last couple days.... with a very low float this one moves easy up or down.. a little positive news and up we go... seems like the .18 area is support now and upticking this am... http://stockcharts.com/h-sc/ui?s=gtha&p=D&yr=0&mn=6&dy=0&id=p85870896926Posts: 660 | From: california | Registered: Nov 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
